← All trials
NCT05558397
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2018
- Primary completion
- Dec 31, 2022
- Completion date
- Aug 31, 2023
- First posted
- Sep 28, 2022
- Last posted
- Sep 28, 2022
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Universidade Federal de AlfenasLead sponsor
- Fundação de Amparo à Pesquisa do estado de Minas GeraisCollaborator
- Universidade Federal de AlfenasReponsible party - principal investigator
- Universidade Federal de AlfenasStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.